Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Augmentation Strategies for Resistant OCD
NCT00466609Phase 4Completed
- Sponsor
- Universidade de São Paulo
- Start
- May 2007
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in obsessive compulsive disorder (OCD) comparing Quetiapine Augmentation, Clomipramine Augmentation and Placebo Control (3 arms). Primary endpoint: Yale-Brown Obsessive Compulsive Scale at 12 weeks. Started May 2007; status: completed.
02
Drugs
quetiapineclomipramine
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT00466609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00466609.